1
|
Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ. Patient Registries in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019; 200:160-167. [PMID: 31034241 PMCID: PMC6635784 DOI: 10.1164/rccm.201902-0431ci] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 04/24/2019] [Indexed: 01/06/2023] Open
Abstract
Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) have been established. These registries are collecting a wealth of longitudinal data on thousands of patients with this rare disease. The data collected in these registries will be complementary to data collected in clinical trials because the patient populations studied in registries have a broader spectrum of disease severity and comorbidities and can be followed for a longer period of time. Maintaining the quality and completeness of registry databases presents administrative and resourcing challenges, but it is important to ensuring the robustness of the analyses. Data from patient registries have already helped improve understanding of the clinical characteristics of patients with IPF, the impact that the disease has on their quality of life and survival, and current practices in diagnosis and management. In the future, analyses of biospecimens linked to detailed patient profiles will provide the opportunity to identify biomarkers linked to disease progression, facilitating the development of precision medicine approaches for prognosis and therapy in patients with IPF.
Collapse
Affiliation(s)
| | - Jürgen Behr
- Department of Internal Medicine V, Ludwig-Maximilians University of Munich, Munich, Germany
- Asklepios Clinic Gauting, Member of the German Center for Lung Research, Gauting, Germany
| | - John A. Belperio
- David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California
| | - Tamera J. Corte
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- University of Sydney, Sydney, New South Wales, Australia
| | | | - Kevin R. Flaherty
- Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan
| | - Mridu Gulati
- Yale University School of Medicine, New Haven, Connecticut
| | | | | | - Jesse Roman
- Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, Pennsylvania
| | | | - Hyun J. Kim
- University of Minnesota, Minneapolis, Minnesota
| |
Collapse
|
2
|
Parker JM, Glaspole IN, Lancaster LH, Haddad TJ, She D, Roseti SL, Fiening JP, Grant EP, Kell CM, Flaherty KR. A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2018; 197:94-103. [DOI: 10.1164/rccm.201704-0784oc] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
| | - Ian N. Glaspole
- Department of General Respiratory Medicine and Lung Transplantation, The Alfred Hospital, Melbourne, Australia
- Department of Medicine, Monash University, Melbourne, Australia
| | - Lisa H. Lancaster
- Allergy, Pulmonary, and Critical Care, Vanderbilt University, Nashville, Tennessee
| | - Tarik J. Haddad
- Pulmonary and Critical Care Medicine, Tampa General Hospital, Tampa, Florida
| | - Dewei She
- Clinical Biostatistics and Data Management
| | | | | | - Ethan P. Grant
- Translational Medicine, MedImmune, Gaithersburg, Maryland
| | - Chris M. Kell
- Product Development, MedImmune, Cambridge, United Kingdom; and
| | - Kevin R. Flaherty
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
| |
Collapse
|